Tysabri

A Win-Win Multiple Sclerosis Deal?
Motley Fool
Thu, 02/7/13 - 10:10 am
MS
multiple sclerosis
Tysabri
Biogen Idec
Elan
Biogen pays Elan $3.25 billion to take over MS drug
Reuters
Wed, 02/6/13 - 08:25 am
Biogen Idec
Elan
Tysabri
M&A
MS
multiple sclerosis
2013 Should Be Interesting for Multiple Sclerosis Drugs
Motley Fool
Thu, 01/3/13 - 11:39 am
MS
multiple sclerosis
Teva
Copaxone
Rebif
Pfizer
Merck KGaA
Biogen Idec
Avonex
Bayer
Betaseron
Novartis
Extavia
Sanofi
Tysabri
Aubagio
Elan
Gilenya
BG-12
Is Biogen Too Good To Be True?
Seeking Alpha
Tue, 09/18/12 - 04:44 pm
BiogenIdec
Avonex
Tysabri
Fampyra
Fumaderm
PDL BioPharma expects 2 percent revenue growth on better sales of Herceptin, Lucentis, Tysabri
Yahoo/AP
Thu, 06/14/12 - 01:22 pm
PDL Biopharma
guidance
Herceptin
Biogen Idec
Lucentis
Tysabri
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s Commitment to Deliver Promising Therapies for Unmet Needs in Neurodegenerative Diseases
Yahoo/BusinessWire
Sat, 04/21/12 - 11:49 am
Biogen
Tysabri
Fampyra
BG-12
multiple sclerosis
amyotrophic lateral sclerosis
DAC HYP
Biogen Idec: The Patriots of Biotechs
PharmExec
Thu, 02/2/12 - 11:06 am
Biogen Idec
Tysabri
Elan
biotech
BG-12
MS
multiple sclerosis
Tysabri label change could add $1B to sales
Fierce Pharma
Mon, 01/23/12 - 12:00 pm
Tysabri
MS
multiple sclerosis
Biogen Idec
Biogen, Elan Win U.S. FDA Approval of Tysabri Label Change to Target Use
Bloomberg
Sat, 01/21/12 - 01:04 pm
Biogen Idec
Elan
Tysabri
multiple sclerosis
22 Hot Drugs Facing FDA Approval in 2012
TheStreet.com
Tue, 11/29/11 - 09:09 am
Amarin
AMR101
Ironwood
linaclotide
Merck
Ariad
ridaforolimus
Vivus
Qnexa
Avanafil
Amgen
Xgeva
Cell Therapeutics
pixantrone
Kalydeco
Vertex
ONYX Pharmaceuticals
Carfilzomib
Pfizer
Bristol-Myers Squibb
Eliquis
Chelsea Therapeutics
Northera
Levadex
MAP Pharmaceuticals
Roche
Curis
vismodegib
Biogen Idec
Elan
Tysabri
Amylin
Bydureon
Dapagliflozin
Uplypso
Protalix BioTherapeutics
Teva Pharmaceuticals
BioSante
Bio-T-Gel
Corlux
Corcept Therapeutics
Discovery Labs
Surfaxin
5 One-Drug Wonders Going for No. 2
Motley Fool
Tue, 11/1/11 - 11:09 am
Dendreon
Provenge
DN24-02
Elan
Tysabri
bapineuzumab
ONYX Pharmaceuticals
Bayer
regorafenib
Carfilzomib
Nexavar
Vertex
Merck
Incivek
Kalydeco
Momenta
Lovenox
Copaxone
Teva Pharmaceuticals
Elan Posts Profit on Tysabri Gains, Sale of Technology Unit
Bloomberg
Thu, 10/27/11 - 11:40 am
Elan
earnings
Tysabri
Biogen Idec, Elan Say FDA Extends Date to Decide Tysabri Change
Bloomberg
Thu, 10/20/11 - 09:17 am
Biogen Idec
FDA
Elan
Tysabri
MS
multiple sclerosis
Analyst upgrades drugmaker Elan on higher expectations for multiple sclerosis drug Tysabri
Yahoo/AP
Thu, 08/25/11 - 08:24 am
Elan
Biogen Idec
MS
Tysabri
multiple sclerosis
FDA: Tysabri risks greatest during year 3
Fierce Pharma
Tue, 04/26/11 - 06:21 am
FDA
Biogen Idec
Tysabri
MS
multiple sclerosis
EU Panel Recommends That Elan Update Tysabri MS Drug Label
Bloomberg
Mon, 04/18/11 - 10:59 am
Europe
Elan
MS
multiple sclerosis
Tysabri
Biogen Test Finds Tysabri Patients With 1% Risk of Getting Brain Disease
Bloomberg
Sat, 04/16/11 - 01:12 pm
Biogen Idec
Tysabri
progressive multifocal leukoencephalopathy
multiple sclerosis
Biogen Test Finds Tysabri Patients With 1% Brain Disease Risk
Bloomberg
Fri, 04/15/11 - 10:36 am
Biogen Idec
Tysabri
Elan Up the Most in 3 Months After Positive Tysabri Comments
Bloomberg
Wed, 04/6/11 - 07:36 pm
Elan
Tysabri
bapineuzumab
Tysabri reports 10 more brain disease cases
Irish Examiner, Ireland
Sat, 02/19/11 - 12:00 pm
Tysabri
Elan
PML
Biogen Idec

Pages